구세영 (Harvard Medical School, 현 협성대학교) | 한빛사논문 > 한빛사

한빛사논문

조회993

Harvard Medical School, 현 협성대학교

CV File 201 kb

Adv. Drug Deliv. Rev., Oct 21 2023, S0169-409X(23)00431-3 | https://doi.org/10.1016/j.addr.2023.115116 Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery

Qimanguli Saiding ^a,1, Zhongyang Zhang ^a,c,1, Shuying Chen ^a, Fan Xiao ^b, Yumeng Chen ^c, Yongjiang Li ^a, Xueyan Zhen ^a, Muhammad Muzamil Khan^a, Wei Chen ^a, Seyoung Koo ^a*, Na Kong ^a,b*, Wei Tao ^a*

^aCenter for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States

^bLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, Zhejiang 311121, China

^cDepartment of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark

¹Qimanguli Saiding and Zhongyang Zhang contributed equally to this work.

*Corresponding authors : Seyoung Koo, Na Kong, Wei Tao

Abstract

Upon entering the biological milieu, nanomedicines swiftly interact with the surrounding tissue fluid, subsequently being enveloped by a dynamic interplay of biomacromolecules, such as carbohydrates, nucleic acids, and cellular metabolites, but with predominant serum proteins within the biological corona. A notable consequence of the protein corona phenomenon is the unintentional loss of targeting ligands initially designed to direct nanomedicines toward particular cells or organs within the in vivo environment. Traditional nanomedicines often focus on encapsulating drugs or therapeutic agents within nanoparticles to enhance their stability, solubility, and extensionofcirculation time; nevertheless, mRNA nanomedicine displays extra high demand for specific cell and tissue-targeted delivery to effectively transport mRNA molecules into target cells, where they can exert their therapeutic effects with utmost efficacy. In this review, focusing on the delivery systems and tissue-specific applications, we aim to update the nanomedicine population with the prevailing and still enigmatic paradigm of nano-bio interactions, a formidable hurdle in the pursuit of targeted mRNA delivery. We also elucidate the current impediments faced in mRNA therapeutics and, by contemplating prospective avenues-either to modulate the corona or to adopt an 'ally from adversary' approach-aim to chart a course for advancing mRNA nanomedicine.

논문정보

형식Review Paper
게재일2023년 10월 (BRIC 등록일 2023-10-26)
연구진국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기